![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 2, 1099-1106, January 11, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Medical Cell Biology, Uppsala
University, Uppsala S-751 23, Sweden
Received for publication, August 29, 2001, and in revised form, November 1, 2001
Stabilization of insulin mRNA in response to
glucose is a significant component of insulin production, but the
mechanisms governing this process are unknown. We presently observe
that insulin mRNA is a highly abundant messenger and that the
content of this mRNA is mainly controlled by changes in messenger
stability. We also demonstrate specific binding of the polypyrimidine
tract-binding protein to a pyrimidine-rich sequence located in the
3'-untranslated region (3'-UTR) of insulin mRNA. This binding was
increased in vitro by dithiothreitol and in
vivo by glucose. Inhibition of polypyrimidine tract-binding
protein binding to the pyrimidine-rich sequence by mutation of the core
binding site resulted in a destabilization of a reporter gene mRNA.
Thus, glucose-induced binding of polypyrimidine tract-binding protein
to the 3'-UTR of insulin mRNA could be a necessary event in the
control of insulin mRNA levels.
Glucose is the main regulator of insulin biosynthesis (1). Besides
controlling insulin biosynthesis by modulating protein synthesis
initiation and elongation rates (2), glucose also stimulates the
production of insulin by increasing insulin mRNA levels (3). This
effect is achieved by a selective stimulation of insulin gene
transcription (4) as well as by an increase in insulin mRNA
stability (5). However, the relative contribution of transcriptional
versus post-transcriptional mechanisms to the control of
insulin mRNA levels is under debate. According to the original
view, insulin mRNA is a highly abundant messenger (6), which is not
affected by short term glucose challenges (7), and therefore controlled
to a large extent by changes in messenger stability (5). The half-life
of insulin mRNA was assessed to be 29 h at a low glucose
concentration and 77 h at a high glucose concentration (5). Recent
observations, however, challenge this view by suggesting that insulin
mRNA contents of insulin-producing cells are rapidly and
dramatically increased by glucose and that this effect is mediated by
stimulation of insulin gene transcription (8-10). In addition, it has
also been reported that glucose destabilizes, rather than stabilizes,
recently formed insulin mRNA (9).
Very little is known on the mechanisms by which glucose, according to
the original view, promotes an increased stability of insulin mRNA.
A recent study has identified the 3'-untranslated (3'-UTR)1 region as a
critical region for glucose-mediated control of rat insulin II mRNA
stability (11). We have observed that the 3'-UTR of rat insulin
mRNA contains a pyrimidine-rich segment directly downstream of the
coding sequence (Fig. 1A).
Interestingly, similar pyrimidine-rich segments are located to the
insulin mRNA 3'-UTR of several mammalian and non-mammalian species
including humans (Fig. 1B). Pyrimidine-rich segments are
also present in 3'-UTRs of other long-lived messengers, such as
The aim of the present study was first to quantify insulin mRNA in
rat pancreatic islets. A high insulin mRNA content would strongly
support the original view that insulin mRNA contents are mainly
controlled by post-transcriptional mechanisms. Second, we aimed at
characterizing the molecular event by which glucose increases insulin
RNA stability. We have therefore studied the putative role of the
pyrimidine-rich insulin mRNA 3'-UTR in the regulation of insulin
mRNA stability.
Materials--
The RNA oligonucleotides were from Scandinavian
Gene Synthesis AB (Köping, Sweden). The rabbit anti-PCBP serum
was a generous gift from the laboratory of Ellie Ehrenfeld. David
Helfman's and Carol Bromstycks' groups kindly supplied the mouse PTB
and rabbit anti-hnRNP K antibodies.
Isolation and Culture of Pancreatic Islets--
Adult
Sprague-Dawley rats, from a local colony, were used. Islets were
isolated by collagenase digestion (17). The islets were cultured in
RPMI 1640 supplemented with 10%, Fetal Clone II serum (Hyclone Europe
Ltd., Cramlington, UK). The islets were cultured free-floating 5-10
days with the medium changed every second day (16).
Human islets were obtained from the Central Unit of the Quantitative Real-time PCR--
Total RNA from 20-30 islets was
isolated using the UltraspecTM Total RNA Isolation System
(Biotech Laboratories, Houston, TX). First strand cDNA was
synthesized using random nonamers and avian myeloblastosis virus
reverse transcriptase (Promega, Madison, WI). PCR reactions were
carried out with the Lightcycler real-time PCR instrument, using the
Faststart DNA Master CYBR Green I kit (Roche Molecular Biochemical,
Mannheim, Germany). The following primers were used: insulin
forward, 5'-ACAGCACCTTTGTGGTCC; insulin reverse,
5'-GGACTCAGTTGCAGTAGTTC;
Electromobility Shift Assay and Cross-linking
Analysis--
The following RNA oligonucleotides were used: ins-PRS,
5'-UCCACCACUCCCCGCCCACCCCUCU; ins-PRS mutant 3, 5'-UCCACCACUCCCCGCCCAAAAAUCU; and human ins-PRS,
5'-CCCCCCACCCGCCGCCUCCU. RNA oligonucleotides (1 pmol) were
kinased using [
Rat islets were homogenized in 100 µl of homogenization buffer (19),
by using a Pellet Pestle® Motor (Kontes, Scientific Glassware/Instruments, Vineland, NJ). The homogenates were centrifuged at 13,000 × g for 10 min. The supernatant was used as
the cytosolic fraction and the pellet as the nuclear fraction. The
pellet was resuspended in an equal volume homogenization buffer
supplemented with 1% Triton X-100.
The RNA-protein binding reaction was performed essentially as described
previously (19). To half the reactions 11 mM
dithiothreitol (DTT) was added, before addition of the probe. In some
cases, the reaction mixtures were divided into two aliquots, one which was cross-linked by exposed to uv radiation (5 milliwatts/cm2) for 5 min and then analyzed by reducing
SDS-PAGE, the other was used directly for non-denaturing gel
electrophoresis. In the latter case, the samples were applied on a 7%
polyacrylamide gel and electrophoresed in 0.5 × TBE (45 mM Tris borate, 1 mM EDTA). The gel was
fixated, dried, and exposed to a film overnight at Elution and Analysis of Gel Slices Containing the RNA
Oligonucleotide-Protein Complex--
RNA oligonucleotide-protein
binding reactions were run on a non-denaturing gel, and the position of
the retarded and radioactive RNA oligonucleotide-protein complex was
visualized by exposing an x-ray film to the gel. The lanes were then
cut in three parts: above, at, and below the RNA-protein complex
position. Proteins were eluted from the gel slices in 5 mM
Tris acetate, pH 8.0, 0.1% SDS, and 0.1 mM EDTA under
agitation overnight. The eluates were then concentrated on Centricon
microconcentrators (Amicon, Beverly, MA), and the proteins were
separated on a 12% SDS-PAGE and electroblotted to a nitrocellulose
filter. The filters were hybridized with the monoclonal anti-PTB 3 antibody (20). Horseradish peroxidase-conjugated anti-mouse antibody
(1:1000) was used as secondary antibody, which was detected by the
Amersham ECL system (Amersham Biosciences, Inc.).
Northwestern Hybridization--
Northwestern was performed
essentially as described previously by others (21). Islet proteins were
separated by 12% SDS-PAGE and transferred to a membrane and renatured
by incubating the membrane in renaturing buffer (21) for 2 h at
room temperature. The membrane was then incubated in hybridization
buffer (renaturing buffer + 20 mg/ml tRNA, 1 mg/ml heparin, and 0.5 nmol of 32P-labeled RNA oligonucleotide) for another 2 h. The membrane was further washed 3 × 10 min in renaturing
buffer, dried, and finally exposed to an x-ray film. The position of
the radioactive band was compared with that of the PTB, which was
visualized by immunoblotting, analyzed in parallel.
Construction of Reporter Gene Vectors with 3'-UTR
Ins-PRS--
Double-stranded DNA oligonucleotides with the
sequences of wild-type ins-PRS (5'-UCCACCACUCCCCGCCCACCCCUCU),
mutant 1 ins-PRS (5'-UCCACCACUCCCCGCCCACCACUCU), or mutant 2 ins-PRS (5'-UCCACCACUCCCCUCCCACCCCUCU) were
synthesized with XbaI restriction sites at both ends. The oligonucleotides were then cloned into the XbaI site of the
pCRTM3-CAT vector (Invitrogen, San Diego, CA), downstream
the coding sequence of the chloramphenicol acetyltransferase
(CAT) reporter gene, and upstream the bovine growth hormone
polyadenylation signal. All vectors were control-sequenced using
dideoxynucleotide termination sequencing and the Sequenace kit (United
States Biochemicals, Cleveland, OH).
Semiquantitative Reverse
Transcriptase-PCR--
Lipofection of dispersed islet cells was
performed essentially as described previously (22). The cells were
transfected with 1 µg of either empty pCR3-CAT vector, pCR3-CAT + wild-type ins-PRS, pCR3-CAT + ins-PRS mutant 1, or pCR3-CAT + ins-PRS
mutant 2 and maintained in culture for 48 h. The cells from each
of the four dishes were then exposed for 24 h to 2.8 or 28 mM glucose, with our without 5 µg/ml actinomycin D.
The cells were collected from the previous step, and the RNA was
isolated using the UltraspecTM Total RNA Isolation reagent.
The You-Prime First-strand Beads kit (Amersham Biosciences, Inc.) was
used for cDNA synthesis. The sequences of the PCR primers
were CAT forward, 5-GAATGCTCATCCGGAACT; CAT reverse,
5'-CCAGGGTCAAGGAAGGCACGG; glyceraldehyde-3-phosphate dehydrogenase
forward, 5'-GACCCCTTCATTGACCTCA; and glyceraldehyde-3-phosphate dehydrogenase reverse, 5'-CCTTCTCCATGGTGGTGAA. When analyzing samples treated with actinomycin D, 30 cycles were required to see PCR
products in the exponential phase. However, for samples not treated
with actinomycin D, 25 cycles were sufficient. The PCR products were
run in an 1.5% agarose gel and stained with ethidium bromide for
quantification of 28 S rRNA.
Insulin mRNA Is Highly Abundant in Rat
Next, we quantified insulin mRNA contents in response to a long
term (24 h) glucose and serum stimulation. The insulin mRNA contents of control islets dropped to ~20,000/
Having established that insulin mRNA is highly abundant and only
slowly increased in response to glucose, we next addressed the question
whether transcriptional or post-transcriptional mechanisms mediate the
regulatory effect of glucose. For this purpose, islets were precultured
in the presence of serum and high glucose to bring the insulin mRNA
contents up to high levels. Next, some of the islets were transferred
to a low glucose-containing medium with or without actinomycin D. As
expected, a 16-h incubation at a low glucose concentration promoted a
small (35%) decrease in insulin mRNA (Fig. 2D).
Interestingly, inhibition of RNA synthesis did not decrease insulin
mRNA contents and the drop induced by low glucose was of the same
magnitude in the presence as in the absence of actinomycin D (Fig.
2D). This correlates well with previous findings showing
that actinomycin D does not markedly reduce insulin mRNA levels
(5). This is possibly explained by inhibition of synthesis of insulin
mRNA degrading factors, which would mask the inhibiting effect on
insulin gene transcription (5). On the other hand, A 55-60-kDa Protein Binds to the Ins-PRS--
The findings that
glucose-induced changes in insulin mRNA stability control insulin
mRNA contents prompted us to next investigate the mechanisms that
regulate insulin mRNA stability. Probing for specific binding to
the pyrimidine-rich insulin mRNA 3'-UTR sequence (ins-PRS), we
observed binding of a 25-bp ins-PRS RNA oligonucleotide to a cytosolic
protein, both in liver and islet cells. This binding resulted in a
cross-linked complex with the combined molecular mass of 65-70
kDa (Fig. 3, A-C). If it were
assumed that the RNA oligonucleotide increases the molecular
mass of the complex with 10 kDa, the molecular mass of the
RNA-binding protein would be 55-60 kDa. This binding was not observed
in the absence of uv cross-linking, nor when a mutated RNA
oligonucleotide, in which four centrally located C were replaced by A
(ins-PRS mutant 3), was used (Fig. 3A). In liver cells,
there was also prominent binding to the ins-PRS RNA oligonucleotide by
a 40-kDa protein (Fig. 3A). The identity of this protein is
not known, but the MW corresponds well to PCBP, which has been reported
to bind to the pyrimidine-rich sequence of TH mRNA (25). Binding of
the 40-kDa protein to the ins-PRS RNA oligonucleotide was, however, not
consistently observed in islet cells (Fig. 3, B and
C).
The Binding Activity of the 55-60-kDa Protein to Ins-PRS Is
Stimulated by Reducing Agents and Glucose--
Using cytosolic
extracts from non-stimulated rat pancreatic islets, we observed that
the reducing agents DTT (Fig. 3B) or
Also human insulin mRNA 3'-UTR contains a pyrimidine-rich motif
(Fig. 1B). To determine whether binding in human islet
cytosol extracts to the human ins-PRS occurs, we analyzed binding
reactions by non-denaturing gel electrophoresis. It was observed that a similar gel retardation product was present in human islet extracts as
in rat islet extracts (Fig. 3E). This indicates that a
similar insulin mRNA 3'-UTR-protein complex is formed in human
islets as in rat islets.
The 55-60-kDa Ins-PRS Binding Protein Is Probably PTB--
To
determine the identity of the ins-PRS-binding protein, we performed
supershift analysis using antibodies specific for hnRNP-K, PCBP, and
PTB. The antibodies against hnRNP-K and PCBP did not generate a
supershift (Fig. 5A, results
not shown). However, two different PTB monoclonal antibodies
specifically abolished the ins-PRS/protein complex, an effect that was
not observed with control ascites fluid (Fig. 5A). This
indicates that antibody binding to PTB blocks PTB binding to the
ins-PRS RNA oligonucleotide.
The Northwestern technique was utilized to probe for ins-PRS binding
activity of proteins immobilized to a nitrocellulose filter. We
observed ins-PRS binding activity of a renatured protein, which
migrated to the same position as PTB (Fig. 5B).
Further evidence in support for PTB as the ins-PRS-binding protein was
obtained by analyzing the presence of PTB at the position of the
ins-PRS-protein complex in a non-denaturing electromobility shift assay
gel. By eluting proteins from above, at and below the position of the
ins-PRS-protein complex, we observed PTB immunoreactivity at the
complex position in samples with ins-PRS probe present during the
binding reaction, but not in samples without (Fig. 5C). The
remaining PTB immunoreactivity was located above and not below the
position of the ins-PRS-protein complex. These results indicate that
the fraction of PTB that binds the ins-PRS RNA oligonucleotide alters
its three-dimensional conformation so that it migrates faster in a
non-denaturing gel.
PTB and Ins-PRS Stability Is Not Affected by DTT or
Glucose--
To exclude the possibility that increased binding of PTB
to ins-PRS is due to altered stability in response to DTT or glucose, islet cell homogenates were incubated for 50 min in homogenization buffer with or without 11 mM DTT. Samples were then
analyzed by immunoblotting using the anti-PTB-3 antibody and
counterstained with Amido Black. It was observed that the in
vitro stability of PTB (Fig.
6A) and ins-PRS (Fig.
6B) was not affected by the addition of DTT. In addition,
islets were incubated for 1 h in medium containing 2.8 or 28 mM glucose, and the amount of expressed PTB was examined by
immunoblotting. We could not observe any differences in PTB expression
between the two groups (Fig. 6C), indicating that a 1-h
incubation period is not sufficient to alter PTB contents.
Inhibition of PTB Binding to Ins-PRS Results in mRNA
Destabilization--
Mutation of the critical pyrimidines to purines
resulted in abolished binding of PTB to ins-PRS in vitro
(Fig. 3A). To assess whether mRNA stability is affected
by PTB binding to ins-PRS in vivo, we lipofected dispersed
rat islet cells with pCRTM-CAT vector with or without
wild-type or mutated ins-PRS. In the presence of actinomycin D, we
observed that the reporter gene mRNA containing the wild-type rat
insulin I ins-PRS was equally abundant as the mRNA lacking ins-PRS
(Fig. 7A). However, a mutation of one of the pyrimidines to a purine in the PTB core-binding site
resulted in a marked destabilization of the mRNA, whereas a
mutation of a purine to a pyrimidine outside the core-binding site had
no effect (Fig. 7A). Similar results were obtained in cells
incubated in the absence of actinomycin D (Fig. 7B),
indicating that transcription of the reporter gene was not affected by
the ins-PRS mutation. In cells expressing wild-type ins-PRS, there was
no increase in reporter gene mRNA levels in response to
glucose.
To our knowledge, this is the first study to quantify insulin
mRNA in isolated pancreatic islets. At physiological conditions, i.e. in the presence of serum, the We did not observe any increase in insulin mRNA in response to a
short term (60 min) glucose stimulation. This is, however, not
surprising considering that insulin mRNA is vastly abundant in
Although glucose is known to specifically increase insulin mRNA
stability (5), little is hitherto known of the molecular mechanisms
underlying this event. However, a recent report identified the 3'-UTR
of insulin mRNA as critical for control of messenger stability
(11). The UUGAA sequence, located between the polyadenylation signal
and the polyadenylation site, was suggested to be important because of
its conservancy (11). Alternatively, a closer analysis of the 3'-UTR of
rat insulin mRNA (Fig. 1A) shows that the region just
up-stream of the polyadenylation signal and downstream of the
termination codon contains a pyrimidine-rich sequence, with similarities to the PTB (27) and PCBP (12, 28) consensus binding
sequences (Fig. 1A). Protein binding to 3'-UTR
pyrimidine-rich segments of for example TH and erythropoetin mRNA
has been implicated in both constitutive and regulated stability
control of the messenger (25, 29). In line with this notion, we have
presently observed specific binding of a 55-60-kDa protein to the
ins-PRS RNA oligonucleotide. Moreover, mutation of one cytidine to an
adenosine in the ins-PRS, which probably prevented protein binding,
resulted in marked destabilization of the CAT reporter gene mRNA.
This is in line with the work by Wicksteed et al., (11) in
which it was shown that the 3'-UTR of insulin mRNA contains
stability determinants that mediated a decreased reporter messenger
stability when expressed in hepatocytes. This raises the possibility
that destabilizing elements of the insulin RNA messenger are masked by
We presently observe that a high glucose concentration, which increases
insulin mRNA contents by stabilizing the messenger, stimulated
protein binding to ins-PRS. This indicates that regulated protein
binding to the ins-PRS element could be a necessary event in
glucose-mediated insulin mRNA stabilization. On the other hand, levels of the reporter gene mRNA remained unaffected after
introduction of the wild-type ins-PRS as well as after culture at a
high glucose concentration. Assuming that dispersed and transfected
islet cells respond to glucose as normal islet cells do, it may be that
the presence of ins-PRS is not sufficient for glucose-induced
stabilization of messenger stability. Thus, there may be a requirement
of other cis-acting mRNA elements to obtain full control of
glucose-induced changes in mRNA stability. The induced stability of
TH mRNA in response to hypoxia is for instance dependent of protein
interactions with both the 3'-UTR and the coding region of the mRNA
(29).
Using specific antibodies, we have presently observed that the
ins-PRS-binding protein is probably PTB. It is not clear why PCBP1 or
PCBP2, which both are present in islet cells (results not shown) and
which may bind ins-PRS in liver cells, do not bind ins-PRS in islet
cell homogenates. PCBP is thought to bind TH mRNA, either at the
PCBP consensus binding sequence present in rat TH mRNA (12) or/and
at the PCBP-hypoxia-inducible protein-binding site present in human TH
mRNA (28) (Fig. 1A). The rat ins-PRS sequence is quite
similar to these PCBP-binding sites (Fig. 1A). Thus, it is
reasonable to assume that PCBP, at least in liver homogenates, could
bind ins-PRS. On the other hand, one or two putative PTB-binding sites
are easily identified in rat ins-PRS (Fig. 1A). In addition,
pyrimidine-rich sequences similar to the PTB consensus binding site,
but not to the PCBP sites, seem to be present in insulin mRNA of
most species with known 3'-UTR sequences (Fig. 1B). Taken
together, this supports our finding that PTB is the main
ins-PRS-binding protein and that this event is evolutionarily conserved.
Species with no ins-PRS are frog, hagfish, and chimpanzee. The frog and
particularly the hagfish are evolutionary distant species that both
have insulin mRNA 3'-UTRs that are several hundred bases long,
suggesting that these mRNAs utilize other mechanisms for messenger
stability control. The chimpanzee, however, has lost 48 bp of its
insulin gene due to a deletion at a site just after the reading frame
(30). This results in a very short 3'-UTR without any pyrimidine-rich
motif. Had it been possible to perform experimental studies with
chimpanzee islets, it would have been very interesting to determine
whether insulin mRNA levels in the chimpanzee are governed by the
same signals as in rodent and human islets. Type 2 diabetes mellitus
has been observed in the chimpanzee and may be more frequent than
expected (31).
The main known function of PTB is to inhibit mRNA splicing (32). In
addition, PTB is thought to play an important role in events such as
cap-independent translation (33), RNA polyadenylation, (34) and RNA
localization (35). The PTB-binding site in insulin mRNA is located
just upstream of the polyadenylation signal, and it is not unlikely
that PTB, in addition to regulation of mRNA stability, is involved
in polyadenylation, transport, and/or translation. Moreover, PTB exists
in three different isoforms, with differential alternative splicing
activity, and PTB homologues with cell type-specific expression
patterns have recently been identified (36). Consequently, the
possibility exists that PTB isoforms and the different PTB homologues
have overlapping but distinct RNA binding specificities and that a
specific PTB isoform or homologue is expressed in Although PTB mRNA expression is up-regulated about five times in
the In summary, we have identified an interaction between the rat insulin I
3'-UTR and the protein PTB, an event that may be necessary for
glucose-induced stabilization of insulin mRNA. Future studies will
hopefully identify additional proteins and cis-acting elements, which
co-operate in mediating a high insulin mRNA stability and availability for translation. Finally, it is possible that disturbances of the insulin mRNA metabolism contribute to the development of diabetes mellitus. Interestingly, the chromosomal localization of the
PTB gene has been assigned to chromosome 14-23-p24.1 (38), which is in
close proximity to the IDDM11 locus in humans (39).
The excellent technical assistance of
Ing-Marie Mörsare and Ing-Britt Hallgren is gratefully acknowledged.
*
This work was supported by grants from the Swedish Medical
Research Council (12X-109, 12X-11564, 72P-12995), the Swedish Diabetes Association, the Nordic Insulin Fund, the Juvenile Diabetes Foundation International, and the Family Ernfors Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, November 5, 2001, DOI 10.1074/jbc.M108340200
The abbreviations used are:
UTR, untranslated region;
PTB, polypyrimidine tract-binding protein;
PCBP, poly(C)-binding protein;
TH, tyrosine hydroxylase;
ins-PRS, insulin
mRNA 3'-UTR pyrimidine-rich sequence;
DTT, dithiothreitol;
CAT, chloramphenicol acetyltransferase.
Control of Insulin mRNA Stability in Rat Pancreatic
Islets
REGULATORY ROLE OF A 3'-UNTRANSLATED REGION PYRIMIDINE-RICH
SEQUENCE*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-globin, (I)-collagen, 15-lipoxygenase, and tyrosine hydroxylase
(TH) (Ref. 12; Fig. 1A). It appears that the 37-39-kDa
poly(C)-binding protein (PCBP), also known as
CP or hnRNP-E, binds
to the pyrimidine-rich motifs of these mRNA, thereby assembling a
ribonucleoprotein complex, the
-complex, which results in
stabilization of the mRNA (13). Another interesting pyrimidine-rich
sequence-binding protein is the 56-kDa polypyrimidine tract-binding
protein (PTB) (14). As other hnRNP proteins, PTB assists in processing,
transport, and translation of mRNAs. However, in insulin-producing
MIN6 cells PTB mRNA contents are increased 5-fold by glucose (15).
This may indicate that the expression of PTB is under cell-specific control and that PTB contributes to the
-cell phenotype as a glucose-responsive secretor of insulin.

View larger version (65K):
[in a new window]
Fig. 1.
A, comparison of PCBP and PTB consensus
binding sequences to pyrimidine-rich 3'-UTR segments of TH and rat
insulin mRNA. Y denotes pyrimidines and N any
nucleotide. Letters in bold mark positions of transitions or
transversions that differ from the PCBP and PTB consensus binding
sequences. B, comparisons of the PTB consensus binding
sequence with preproinsulin mRNA pyrimidine-rich 3'-UTR sequences
located downstream of end of coding sequence and upstream of poly(A)
signal. Letters in bold mark positions of transitions that
differ from the PTB consensus binding sequence.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Cell
Transplant, Brussels, where the islets were isolated and maintained in
culture as described previously (17).
-actin forward, 5'-GCCCTGGCTCCTAGCACC;
-actin reverse, 5'-CCACCAATCCACACAGAGTACTTG. Unknown samples were run in duplicates against an external standard curve with known
quantities of linearized pRI7 plasmid, which contains the rat insulin
cDNA (18), or linearized
-actin cDNA plasmid. The amplification efficiency was similar for the reverse-transcribed islet
RNA samples and pRI7 (Fig.
2A).

View larger version (18K):
[in a new window]
Fig. 2.
Real-time PCR quantification of insulin
mRNA contents. A, amplification efficiency of
linearized pRI7 plasmid insulin cDNA and rat islet insulin cDNA
samples in real-time PCR reactions. Series of 10-fold dilutions were
analyzed in duplicates. B, precultured rat pancreatic islets
were maintained for 24 h at 1.7 mM glucose and in the
absence of serum. Islets, in groups of 20-30, were then stimulated for
60 min with 17 mM glucose or 5 µg/ml insulin. Insulin
mRNA,
-actin mRNA, and
-cell number were quantified as
described under "Experimental Procedures." Results are means ± S.E. for six independent observations. C, precultured rat
islets were maintained for 24 h at 1.7 mM glucose and
in the absence of serum. The islets were then stimulated for 24 h
with 17 mM glucose or with 10% Fetal Clone II. Results are means ± S.E. for six independent
observations. D, precultured rat islets were maintained for
24 h at 17 mM glucose in the presence of serum. The
islets were then transferred to 1.7 mM glucose with or
without the presence of 5 µg/ml actinomycin D for 16 h. Results
are means ± S.E. for eight observations. * denotes
p < 0.05 using Student's paired t test.
+ denotes p < 0.05 using one-way analysis
of variance and Bonferroni's test.
-Cell number per islet was determined using flow cytometry. Briefly,
islets were trypsinized for 5 min at 37 °C to generate free islet
cells. The cells were then fixated for 5 min in 4% paraformaldehyde,
permeabilized with 1% saponin, and incubated for 20 min at room
temperature with a guinea pig anti-insulin antibody. A fluorescein
isothiocyanate-labeled anti-guinea pig antibody was added, and the
cells were analyzed in a FACSCalibur flow cytometer (Becton-Dickinson
Instruments). Cells with increased FL1-fluorescence were
gated and counted as
-cells.
-32P]ATP (5000 Ci/mmol, Amersham
Biosciences, Inc., Uppsala, Sweden) and bacteriophage T4
polynucleotide kinase (Sigma-Aldrich). The radiolabeled probes were
purified on Chroma spin-10 columns (CLONTECH Laboratories Inc., Palo Alto, CA).
70 °C.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Cells--
Using
real-time PCR, insulin mRNA contents of in vitro
cultured rat pancreatic islets were quantified. We first assessed basal and non-stimulated insulin mRNA levels by preculturing the islets for 24 h at a substimulatory glucose concentration and in the absence of serum. At these basal conditions, we observed that a
-cell contains 40,000-50,000 insulin mRNA molecules and that insulin mRNA is 60-80 times more frequent than the messenger for
-actin (Fig. 2B). In line with this, a short term (1 h)
stimulation with a high glucose concentration did not increase the
contents of insulin mRNA (Fig. 2B). Insulin has recently
been reported to potently stimulate insulin gene transcription (8-10).
However, addition of 5 µg/ml insulin did not affect insulin mRNA
contents (Fig. 2B). These insulin mRNA estimates
are based upon the assumption that the yield and efficiency of the
RNA extraction and cDNA synthesis procedures are 100%. Our results
might therefore be underestimates.
-cell (Fig.
2C). This is not surprising, because prolonged culture
without glucose and serum (24 h + 24 h) is known to result in
-cell apoptosis (23). The 24-h high glucose stimulation increased
insulin mRNA contents to ~100,000/
-cell (Fig. 2C).
Also the ratio insulin mRNA to
-actin mRNA was markedly
increased (Fig. 2C).
-actin mRNA
did not decrease in response to low glucose and the actinomycin
D-induced decrease was more pronounced than that of insulin mRNA
(Fig. 2D). Consequently, the low glucose-induced decrease in
the insulin mRNA/
-actin mRNA ratio was of the same relative
magnitude both with and without actinomycin D (Fig. 2D).
These findings are in line with the previously established insulin
mRNA half-life of 29 h at a low glucose concentration, 77 h at a high glucose concentration, and a
-actin mRNA half-life of 9 h (5, 24).

View larger version (28K):
[in a new window]
Fig. 3.
Binding activity to the ins-PRS RNA
oligonucleotide in liver and rat islet extracts. A, rat
liver extract was incubated with 32P-labeled wild-type or
mutant 3 ins-PRS RNA oligonucleotide. 11 mM DTT was added
to some of the samples. Following the binding reaction, some of the
samples were uv-cross-linked and analyzed by SDS-PAGE. The
arrowhead to the right indicates the position of
the 65-70-kDa protein-RNA oligonucleotide complex. Below this complex
can also be seen the 50-kDa protein-RNA oligonucleotide complex.
B, islet cytosolic extracts were incubated with wild-type
ins-PRS RNA oligonucleotide with or without 11 mM DTT and
with different concentrations of the molecular cross-linker suberic
acid bis(N-hydroxysuccinimide ester). The
arrowhead to the right indicates the position of
the 65-70-kDa protein-RNA oligonucleotide complex. C, rat
islets were incubated for 60 min at 1 or 28 mM glucose.
Cytosolic extracts were then prepared and allowed to bind to wild-type
ins-PRS RNA oligonucleotide in the presence or absence of DTT. Each
sample was subsequently divided into two aliquots, of which one was
uv-cross-linked and the other was not (D). Non-cross-linked
samples were analyzed by non-denaturing gel electrophoresis.
E, islet cytosol extracts from rat and human islets were
incubated with rat ins-PRS or human ins-PRS 32P-labeled RNA
oligonucleotides, respectively. Binding reactions were analyzed by
non-denaturing gel electrophoresis.
-mercaptoethanol
(data not shown) increased binding of the 55-60-kDa protein to
ins-PRS. The enhancing effect of DTT was dose-dependent and
reached maximum at 5-10 mM (data not shown). The increased binding of the 55-60-kDa protein to ins-PRS in response to DTT was
also observed when binding reactions were analyzed by non-denaturing gel electrophoresis (Fig. 3D). In this case, binding was
visualized by retardation of the radioactive RNA oligonucleotide, and
the intensity of the retarded band corresponded well to the intensity of the 65-70-kDa protein-RNA oligonucleotide complex observed in
parallel cross-linking experiments (Fig. 3, C and
D). The effect of reducing agents was not as clear in islet
homogenates stimulated with a high glucose concentration as compared
with non-stimulated islets (Fig. 3, C and D).
Instead, the ins-PRS binding activity of glucose-stimulated islets was
enhanced in the absence of DTT and not further increased in the
presence of DTT. These findings suggest that the ins-PRS binding
activity is maximally stimulated in the presence of DTT and that
differences observed in binding activity in the absence of DTT may
reflect the in vivo activity of the 55-60-kDa protein.
Thus, by expressing ins-PRS binding activity as the ratio binding
activity
DTT/+DTT, we correct for differences in total amount of the
55-60-kDa protein present in islet samples. When analyzing the effect
of glucose, it was found that the ins-PRS binding activity in rat islet
cytosol was significantly increased by 28 mM, but not by 5 mM glucose (Fig. 4). In
nuclear extracts, both 5 and 28 mM glucose increased
ins-PRS binding activity as compared with no glucose (Fig. 4). Thus,
glucose-induced stabilization of insulin mRNA is paralleled by
increased binding of the 55-60-kDa protein to ins-PRS.

View larger version (38K):
[in a new window]
Fig. 4.
Glucose increases ins-PRS binding activity in
both rat islet cytosol and nuclei fraction. A, isolated
rat islets were incubated for 60 min with different glucose
concentrations and then fractionated into nuclei and cytosol. The
different fractions were incubated with the 32P-labeled
ins-PRS RNA oligonucleotide, with and without DTT, and then separated
with non-denaturating gel electrophoresis. Ins-PRS binding activity was
expressed as ratio between the shifted ins-PRS-protein complex without
and with DTT. Results are mean ± S.E. for six to seven
observations. * denotes p < 0.05 versus indicated control using two-way analysis of variance
and Bonferroni's test. B, photograph showing a typical
experiment.

View larger version (47K):
[in a new window]
Fig. 5.
PTB is probably the ins-PRS-binding
protein. A, islet cytosolic extracts were incubated
with normal rabbit serum (lane 2), control ascites fluid
(lane 3), PCBP antiserum (40) (lane 4), or
anti-PTB monoclonal antibodies 3 or 6 (19) (lanes 5 and
6) for 20 min. 32P-Labeled ins-PRS RNA
oligonucleotide was then added. Complexes were separated by
non-denaturating polyacrylamide gel electrophoresis. B,
islet proteins were separated by SDS-12% PAGE and transferred to a
filter. The left lane shows an immunoblot with a PTB
antibody (IB). The right lane shows Northwestern
hybridization using a 32P-labeled ins-PRS RNA
oligonucleotide (NW). C, electromobility shift
assay was performed, and the gel was cut in different slices. The
proteins in this gel slices were then eluted and separated with a
SDS-12% PAGE and transferred to a membrane. PTB was detected with the
anti-PTB-3 mouse monoclonal antibody. Lane 1 is whole islet
extract, lanes 2 and 4 are ins-PRS complex
position, lane 3 and 5 are below ins-PRS complex
position, lanes 6 and 7 are above ins-PRS complex
position. Lanes 1-3 and 6 are with ins-PRS probe
and remaining lanes are without.

View larger version (39K):
[in a new window]
Fig. 6.
PTB and ins-PRS stability are not affected by
DTT or glucose. A, islet cell homogenates were
incubated for 50 min with or without 11 mM DTT as described
under "Experimental Procedures" and as shown in Figs. 4 and 5.
Samples were analyzed by immunoblotting using the anti-PTB-3 monoclonal
antibody (upper panel). Total protein was visualized by
Amido Black staining (lower panel). B, the
32P-labeled ins-PRS RNA oligonucleotide was incubated as
described above and analyzed by 15% PAGE followed by autoradiography.
C, islets were incubated for 60 min in 2.8 or 28 mM glucose and then homogenized in SDS/
-mercaptoethanol
sample buffer for immunoblot and Amido Black analysis as given above.
Results are representative for two independent experiments.

View larger version (18K):
[in a new window]
Fig. 7.
Mutation of ins-PRS core-binding site leads
to reporter CAT mRNA destabilization. Rat islet cells were
transfected with four different constructs: the empty
pCRTM3-CAT vector, the pCRTM3-CAT vector with
wild-type, mutant 1, or mutant 2 ins-PRS inserted into the 3'-UTR. Two
days after the transfection, the islets were incubated for 24 h at
2.8 or 28 mM glucose with (A) or without
(B) 5 µg/ml actinomycin D. Reverse
transcriptase-PCR was performed for CAT mRNA,
glyceraldehyde-3-phosphate dehydrogenase mRNA, and
-actin
mRNA. Results are mean ± S.E. for three to four
experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cell content of
insulin mRNAs was at least 40,000-100,000 molecules, depending
upon the glucose concentration of the culture medium. This finding is
in agreement with the early and indirect assessment (6), which
indicated a
-cell insulin mRNA content of 50,000-150,000
molecules. A typical mammalian cell contains ~360,000 mRNAs in
its cytoplasm (26). Assuming that the same number applies to the
-cell, insulin mRNA would constitute up to 30% of all mRNA,
which correlates well with the percentage of insulin protein
synthesized (1).
-cells. The transcriptional output of insulin mRNA by the two
insulin genes present in rat has not been determined experimentally. However, a theoretical calculation of the maximal insulin mRNA synthesis rate tells us that no more than 2500 transcripts/h are produced. This assessment is based upon an elongation rate of 30 nucleotides per second and that 10 RNA polymerases transcribe each
insulin gene simultaneously. Although this is most likely an
overestimate, it is far from the net increase of 40000 molecules, which
is the minimum number of molecules necessary to double the insulin
mRNA content of low glucose cultured islets in 1 h. In our
hands, the insulin mRNA content is only slightly decreased by a
16 h glucose withdrawal. The same decrease was observed in islets
with inhibited RNA polymerase activity. This indicates that control of
insulin mRNA stability contributes significantly to the regulation
of insulin mRNA levels. Indeed, it is generally agreed that the
contents of abundant and long lived messengers are subject to
post-transcriptional, rather than transcriptional control. This view is
challenged by Leibiger and co-workers (8-10), who report that insulin
mRNA contents are increased up to 5-fold in response to a 60-min
glucose stimulation. The reason for the apparent incompatibilities
between the present work and the work by the Leibiger group is unclear.
-cell-specific protein binding to the ins-PRS sequence.
-cells with the
purpose to modulate insulin mRNA levels.
-cell line MIN6, in response to a 24-h glucose stimulation (15),
we could not detect any differences in protein expression after a 1-h
incubation at different glucose concentrations. This suggests that
acute alterations in the PTB binding activity is regulated by
post-translational modifications rather than by increased PTB gene
expression. Furthermore, PTB is known to interact with other members of
the hnRNP family such as hnRNP-E2 (PCBP 2), -K, and -L, which are all
expressed in islets (Refs. 33 and 37, present results). Thus, the
interaction of PTB with additional RNA-binding proteins may be
necessary events in glucose-mediated regulation of insulin mRNA stability.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of Medical Cell
Biology, Uppsala University, Biomedicum, P. O. Box 571, SE-751 23 Uppsala, Sweden. Tel.: 46-18-4714212; Fax: 46-18-556401; E-mail:
Nils.Welsh@medcellbiol.uu.se.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Ashcroft, S. J.,
Bunce, J.,
Lowry, M.,
Hansen, S. E.,
and Hedeskov, C. J.
(1978)
Biochem. J.
174,
517-526
2.
Welsh, M.,
Scherberg, N.,
Gilmore, R.,
and Steiner, D. F.
(1986)
Biochem. J.
235,
459-467
3.
Brunstedt, J.,
and Chan, S. J.
(1982)
Biochem. Biophys. Res. Commun.
106,
1383-1389
4.
Nielsen, D. A.,
Welsh, M.,
Casadaban, M. J.,
and Steiner, D. F.
(1985)
J. Biol. Chem.
260,
13585-13589
5.
Welsh, M.,
Nielsen, D. A.,
MacKrell, A. J.,
and Steiner, D. F.
(1985)
J. Biol. Chem.
260,
13590-13594
6.
Giddings, S. J.,
Chirgwin, J.,
and Permutt, M. A.
(1985)
Diabetologia
28,
343-347
7.
Itoh, N.,
Sei, T.,
Nose, K.,
and Okamoto, H.
(1978)
FEBS Lett.
93,
343-347
8.
Leibiger, I. B.,
Leibiger, B.,
Moede, T.,
and Berggren, P.-O.
(1998)
Mol. Cell
1,
933-938
9.
Leibiger, B.,
Moede, T.,
Schwarz, T.,
Brown, G. R.,
Kohler, M.,
Leibiger, I. B.,
and Berggren, P. O.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
4,
9307-9312
10.
Leibiger, B.,
Wahlander, K.,
Berggren, P.-O.,
and Leibiger, I. B.
(2000)
J. Biol. Chem.
275,
30153-30156
11.
Wicksteed, B.,
Herbert, T. P.,
Alarcon, C.,
Lingohr, M. K.,
Moss, L. G.,
and Rhodes, C. J.
(2001)
J. Biol. Chem.
276,
22553-22558
12.
Holcik, M.,
and Liebhaber, S. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2410-2414
13.
Wang, X.,
Kiledjian, M.,
Weiss, I.,
and Liebhaber, S. A.
(1995)
Mol. Cell. Biol.
15,
1769-1777
14.
Valcarcel, J.,
and Gebauer, F.
(1997)
Curr. Biol.
7,
705-708
15.
Webb, G. C.,
Akbar, M. S.,
Zhao, C.,
and Steiner, D. F.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5773-5778
16.
Andersson, A.
(1978)
Diabetologia
14,
397-404
17.
Eizirik, D. L.,
Welsh, N.,
and Hellerstrom, C.
(1993)
J. Clin. Endocrinol. Metab.
76,
399-403
18.
Chan, S. J.,
Noyes, B. E.,
Agarwal, K. L.,
and Steiner, D. F.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
5036-5040
19.
Czyzyk-Krzeska, M. F.,
Dominski, Z.,
Kole, R.,
and Millhorn, D. E.
(1994)
J. Biol. Chem.
269,
9940-9945
20.
Grossman, J. S.,
Meyer, M. I.,
Wang, Y. C.,
Mulligan, G. J.,
Kobayashi, R.,
and Helfman, D. M.
(1998)
RNA (N. Y.)
4,
613-625
21.
Stefanovic, B.,
Hellerbrand, C.,
Holcik, M.,
Briendl, M.,
Aliebhaber, S.,
and Brenner, D. A.
(1997)
Mol. Cell. Biol.
17,
5201-5209
22.
Saldeen, J.,
Curiel, D. T.,
Eizirik, D. L.,
Andersson, A.,
Strandell, E.,
Buschard, K.,
and Welsh, N.
(1996)
Diabetes
45,
1197-1203
23.
Hoorens, A.,
Van de Casteele, M.,
Kloppel, G.,
and Pipeleers, D.
(1996)
J. Clin. Invest.
98,
1568-1574
24.
Chen, M.,
Schnermann, J.,
Smart, A. M.,
Brosius, F. C.,
Killen, P. D.,
and Briggs, J. P.
(1993)
J. Biol. Chem.
268,
24138-24144
25.
Czyzyk-Krzeska, M. F.,
and Bendixen, A. C.
(1999)
Blood
93,
2111-2120
26.
Alberts, B.,
Bray, D.,
Lewis, J.,
Raff, M.,
Roberts, K.,
and Watson, J. D.
(1994)
Molecular Biology of the Cell
, Third Ed.
, p. 369, Garland Publishing, Inc., New York
27.
Singh, R.,
Valcarcel, J.,
and Green, M. R.
(1995)
Science
268,
1173-1176
28.
Czyzyk-Krzeska, M. F.,
and Beresh, J. E.
(1996)
J. Biol. Chem.
271,
3293-3299
29.
Paulding, W. R.,
and Czyzyk-Krzeska, M. F.
(1999)
J. Biol. Chem.
274,
2532-2538
30.
Seino, S.,
Bell, G. I.,
and Li, W-H.
(1992)
Mol. Biol. Evol.
9,
193-203
31.
Rosenblum, I. Y.,
Barbolt, T. A.,
and Howard, C. F., Jr.
(1981)
J. Med. Primatol.
10,
93-101
32.
Wagner, E. J.,
and Garcia-Blanco, M. A.
(2001)
Mol. Cell. Biol.
21,
3281-3288
33.
Kim, Y. K.,
Hahm, B.,
and Jang, S. K.
(2000)
J. Mol. Biol.
304,
119-133
34.
Moreira, A.,
Takagaki, Y.,
Brackenridge, S.,
Wollerton, M.,
Manley, J. L.,
and Proudfoot, N. J.
(1998)
Genes Dev.
12,
2522-2534
35.
Cote, C. A.,
Gautreau, D.,
Denegre, J. M.,
Kress, T. L.,
Terry, N. A.,
and Mowry, K. L.
(1999)
Mol. Cell.
4,
431-437
36.
Wollerton, M. C.,
Gooding, C.,
Robinson, F.,
Brown, E. C.,
Jackson, R. J.,
and Smith, C. W. J.
(2001)
RNA (N. Y.)
7,
819-832
37.
Kamma, H.,
Portman, D. S.,
and Dreyfuss, G.
(1995)
Exp. Cell Res.
221,
187-196
38.
Raimondi, E.,
Romanelli, M. G.,
Moralli, D.,
Gamberi, C.,
Russo, M. P.,
and Morandi, C.
(1995)
Genomics
27,
553-555
39.
Field, L. L.,
Tobias, R.,
Thomson, G.,
and Plon, S.
(1996)
Genomics
33,
1-8
40.
Blyn, L. B.,
Towner, J. S.,
Semler, B. L.,
and Ehrenfeld, E.
(1997)
J. Virol.
71,
6243-6246
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Xu, J. R. McCarrey, and N. B. Hecht A cytoplasmic variant of the KH-type splicing regulatory protein serves as a decay-promoting factor for phosphoglycerate kinase 2 mRNA in murine male germ cells Nucleic Acids Res., November 10, 2008; (2008) gkn800v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xu and N. B. Hecht Polypyrimidine Tract Binding Protein 2 Stabilizes Phosphoglycerate Kinase 2 mRNA in Murine Male Germ Cells by Binding to Its 3'UTR Biol Reprod, June 1, 2007; 76(6): 1025 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Evans-Molina, J. C. Garmey, R. Ketchum, K. L. Brayman, S. Deng, and R. G. Mirmira Glucose Regulation of Insulin Gene Transcription and Pre-mRNA Processing in Human Islets Diabetes, March 1, 2007; 56(3): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Van Lommel, K. Janssens, R. Quintens, K. Tsukamoto, D. Vander Mierde, K. Lemaire, C. Denef, J.-C. Jonas, G. Martens, D. Pipeleers, et al. Probe-Independent and Direct Quantification of Insulin mRNA and Growth Hormone mRNA in Enriched Cell Preparations Diabetes, December 1, 2006; 55(12): 3214 - 3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E Cerf Transcription factors regulating {beta}-cell function. Eur. J. Endocrinol., November 1, 2006; 155(5): 671 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pautz, K. Linker, T. Hubrich, R. Korhonen, S. Altenhofer, and H. Kleinert The Polypyrimidine Tract-binding Protein (PTB) Is Involved in the Post-transcriptional Regulation of Human Inducible Nitric Oxide Synthase Expression J. Biol. Chem., October 27, 2006; 281(43): 32294 - 32302. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Poitout, D. Hagman, R. Stein, I. Artner, R. P. Robertson, and J. S. Harmon Regulation of the Insulin Gene by Glucose and Fatty Acids J. Nutr., April 1, 2006; 136(4): 873 - 876. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Le Sommer, M. Lesimple, A. Mereau, S. Menoret, M.-R. Allo, and S. Hardy PTB Regulates the Processing of a 3'-Terminal Exon by Repressing both Splicing and Polyadenylation Mol. Cell. Biol., November 1, 2005; 25(21): 9595 - 9607. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Baudouin-Legros, A. Hinzpeter, A. Jaulmes, F. Brouillard, B. Costes, P. Fanen, and A. Edelman Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3'UTR part of transcripts Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1240 - C1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Hamano, M Awaji, and H Usuki cDNA structure of an insulin-related peptide in the Pacific oyster and seasonal changes in the gene expression J. Endocrinol., October 1, 2005; 187(1): 55 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. H. Ing Steroid Hormones Regulate Gene Expression Posttranscriptionally by Altering the Stabilities of Messenger RNAs Biol Reprod, June 1, 2005; 72(6): 1290 - 1296. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Florez, O. M. Sessions, E. J. Wagner, M. Gromeier, and M. A. Garcia-Blanco The Polypyrimidine Tract Binding Protein Is Required for Efficient Picornavirus Gene Expression and Propagation J. Virol., May 15, 2005; 79(10): 6172 - 6179. [Abstract] [Full Text] [PDF] |
||||
![]() |